A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors.
A simple blood test may help doctors identify which advanced cancer patients will respond best to immunotherapy, potentially sparing others from ineffective treatment.
In 2040 patients with advanced solid tumors receiving ICIs, clonal hematopoiesis of indeterminate potential — detectable by routine liquid biopsy — was associated with meaningfully longer ICI treatment duration, particularly in patients with TET2 mutations. The findings position CHIP, which is already co-detected on many liquid biopsy panels, as a potential clinically actionable biomarker for predicting who benefits most from checkpoint immunotherapy.
What the study was
- Study design
- Retrospective real-world cohort
- Population
- Advanced solid tumor patients treated with ICI (with or without chemotherapy) who underwent liquid biopsy-based gene panel testing
- Sample size
- 2040
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Cancer
Why it surfaced
Large real-world cohort (n=2040) establishing CHIP—particularly TET2—as a predictive biomarker for ICI benefit in solid tumors; liquid biopsy co-detection makes this immediately actionable without additional testing infrastructure.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.